Scilex Holding (SCLX) Cost of Revenue (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Cost of Revenue of $4.4 million for Q1 2026, up 221.32% year-over-year from $1.4 million in Q1 2025, and up 70.12% quarter-over-quarter from $2.6 million in Q4 2025.
Scilex Holding (SCLX) Cost of Revenue (2022 - 2026) Analysis & Trends
Scilex Holding's Cost of Revenue history runs 5 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 221.32% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $13.7 million (down 4.01% YoY), while the FY2025 annual figure was $10.6 million, down 36.49% from the prior year.
- Cost of Revenue for Q1 2026 stood at $4.4 million, up from $2.6 million in the prior quarter.
- The five-year high for Cost of Revenue was $4.7 million in Q4 2024, with the low at $1.1 million in Q1 2022.
- The 5-year median for Cost of Revenue is $3.6 million (2022), against an average of $3.4 million.
- The sharpest annual moves came in 2025 and 2026: Cost of Revenue tumbled 63.96% in 2025, then soared 221.32% in 2026.
- Scilex Holding's Cost of Revenue stood at $4.5 million in 2022, then gained by 0.18% to $4.5 million in 2023, then advanced by 3.76% to $4.7 million in 2024, then plunged by 44.28% to $2.6 million in 2025, then surged by 70.12% to $4.4 million in 2026.
- Business Quant data shows SCLX's Cost of Revenue at $4.4 million in Q1 2026, $2.6 million in Q4 2025, and $3.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.05 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 4.29 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.40 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.71 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.52 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.81 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.58 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.04 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 3.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.45 Mn |
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Dec 31, 2023 | 4.52 Mn |
| Dec 31, 2023 | 4.52 Mn |